Sarepta Therapeutics (SRPT) Other Accumulated Expenses (2010 - 2026)

Sarepta Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 70.43% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (down 70.43% YoY), while the FY2025 annual figure was $7.0 million, down 48.3% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $4.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $17.1 million in Q2 2024, with the low at $4.3 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $10.2 million (2025), against an average of $9.9 million.
• The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses surged 228.94% in 2022, then tumbled 70.43% in 2026.
• Sarepta Therapeutics' Other Accumulated Expenses stood at $5.3 million in 2022, then soared by 127.14% to $12.1 million in 2023, then grew by 11.62% to $13.5 million in 2024, then sank by 48.3% to $7.0 million in 2025, then slumped by 33.51% to $4.6 million in 2026.
• Business Quant data shows SRPT's Other Accumulated Expenses at $4.6 million in Q1 2026, $7.0 million in Q4 2025, and $10.2 million in Q3 2025.